Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 508.82M | 434.41M | 362.80M | 282.21M | 249.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 508.82M | 434.41M | 362.80M | 282.21M | 249.38M |
| Cost of Revenue | 20.16M | 12.93M | 15.55M | 11.52M | 12.80M |
| Gross Profit | 488.66M | 421.48M | 347.24M | 270.69M | 236.58M |
| SG&A Expenses | 359.27M | 342.14M | 322.95M | 305.54M | 292.94M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 720.87M | 710.37M | 718.75M | 723.10M | 735.66M |
| Operating Income | -212.05M | -275.95M | -355.96M | -440.89M | -486.28M |
| Income Before Tax | -65.86M | -127.43M | -204.95M | -287.66M | -506.01M |
| Income Tax Expenses | 1.23M | 616.00K | 540.00K | 628.00K | 968.00K |
| Earnings from Continuing Operations | -67.09 | -128.05 | -205.49 | -288.29 | -506.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -67.09M | -128.05M | -205.49M | -288.29M | -506.98M |
| EBIT | -212.05M | -275.95M | -355.96M | -440.89M | -486.28M |
| EBITDA | -195.75M | -262.13M | -343.13M | -428.10M | -474.61M |
| EPS Basic | -1.02 | -2.06 | -3.37 | -4.77 | -8.37 |
| Normalized Basic EPS | -2.62 | -3.22 | -4.04 | -4.92 | -5.40 |
| EPS Diluted | -1.07 | -2.11 | -3.42 | -4.82 | -8.37 |
| Normalized Diluted EPS | -2.59 | -3.19 | -4.01 | -4.89 | -5.40 |
| Average Basic Shares Outstanding | 251.42M | 248.71M | 246.01M | 243.67M | 242.22M |
| Average Diluted Shares Outstanding | 253.64M | 250.93M | 248.23M | 245.90M | 242.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |